Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Significant Drop in Short Interest

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 27,400 shares, a decline of 13.0% from the September 30th total of 31,500 shares. Approximately 2.0% of the shares of the company are sold short. Based on an average daily volume of 51,600 shares, the short-interest ratio is presently 0.5 days.

Avenue Therapeutics Price Performance

Avenue Therapeutics stock opened at $2.45 on Wednesday. The business has a 50 day simple moving average of $2.45 and a 200-day simple moving average of $3.50. Avenue Therapeutics has a 12 month low of $1.70 and a 12 month high of $29.25. The stock has a market capitalization of $3.51 million, a PE ratio of -0.31 and a beta of -0.17.

Avenue Therapeutics (NASDAQ:ATXI) last announced its quarterly earnings data on Friday, August 9th. The company reported ($6.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($5.38).

Institutional Investors Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC bought a new position in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned approximately 1.17% of Avenue Therapeutics at the end of the most recent quarter. 17.34% of the stock is owned by hedge funds and other institutional investors.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.